Plasma WFDC2 concentrations were significantly elevated in patients with cancer compared with healthy donors (p < 0.0001, Wilcoxon test), suggesting its potential utility as a diagnostic biomarker (Figure 3A). Here, WFDC2 is linked to cancer.